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Abstract 
Purpose: To evaluate synergy in the analgesic effects of a combination therapy of carbamazepine 
(CBZ) and gabapentin (GBP) in diabetic neuropathic pain.  
Methods: Neuropathic pain was produced in rats by a single intraperitoneal injection of streptozotocin 
(STZ) at 60 mg/kg.  CBZ, GBP, and their combination were orally administered at varying doses (GBP 
30 - 180 mg/kg; CBZ 20 - 40 mg/kg) comparable to their therapeutic doses in humans. Nociceptive 
responses in the diabetic rats were assessed using hot plate test. 
Results: Hot plate latency significantly increased with oral administration of GBP at a dose of 180 
mg/kg when compared with control group (p < 0.05), while at a dose of 90 mg/kg, the increase was not 
significant. Oral administration of CBZ at doses of 20 and 40 mg/kg did not produce any significant 
impact on hot plate latency. However, a combination of GBP at 90 mg/kg and CBZ at 20 mg/kg 
produced significant increase in latency, compared with control group and other groups (p < 0.05), 
except the group that received 180 mg/kg GBP. The combination of low dose GBP 30 mg/kg and 
carbamazepine 30 mg/kg had no significant effect on latency (p > 0.05). 
Conclusion: The results obtained in this study provide useful information on the combination therapy of 
GBP and CBZ, which may be applied in the treatment of pain in diabetic neuropathy. 
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INTRODUCTION 
 
Diabetic neuropathy is a common and costly 
complication of both types of diabetes (I and II). 
The prevalence of neuropathy is about 8 % in 
newly diagnosed patients and greater than half of 
patients with long-standing diabetes [1]. 
Increasing evidence suggest that pre-diabetic 
conditions are also associated with some forms 
of neuropathy [2]. An estimated 15 % of all 
patients with diabetes will develop foot ulcers; 
diabetic neuropathy is the leading cause of non-
traumatic limb amputation [3]. 
 
A variety of anticonvulsants and local anaesthetic 
drugs suppress abnormal discharge originating 
at nerve injury sites and associated dorsal root 
ganglions (DRGs) via sodium channel blockage. 
These include CBZ, phenytoin, tocainide, and 
lidocaine [4].  CBZ is the first antiepileptic drug 
utilized in many clinical trials and has been used 
for long to manage diabetic neuropathy pain [5]. 
Earlier studies recommended that CBZ might be 
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effective in diabetic neuropathy and, in France; 
CBZ is endorsed for treating neuropathic pain in 
adults. The normal therapeutic dose of CBZ is 
between 600 and 1600 mg/day, initially at 200 
mg/day, which is gradually increased every three 
days by 200 mg/day, depending on the unwanted 
effects and response [6]. CBZ appears to limit 
the repetitive firing of action potentials evoked by 
a sustained depolarization by slowing down the 
rate of recovery of voltage-activated Na+ 
channels [7]. 
 
GBP is an anticonvulsant drug with an 
established outcome against diabetic 
neuropathic pain [8]. It was used for many years 
in the treatment of partial epilepsy and was the 
approved medication for neuropathic pain in the 
UK. It is well accepted and appears to be 
effective at a daily dose of 1800 mg. GBP, a 
synthetic analogue of the neurotransmitter Ɣ-
aminobutyric acid (GABA) does not interact 
specifically with GABA receptors but rather 
modulates the activity of high-threshold calcium 
channels, and is successful in relieving indices of 
allodynia and hyperalgesia in animal models [9]. 
Moreover, GBP has mild side effects profile. In 
view of the consequences of these qualities, 
GBP ought to be considered a first‐line treatment 
for neuropathic pain. Evidence of the adequacy 
of anticonvulsant medications in the treatment of 
neuropathic pain are on the increase, and have 
been clearly demonstrated with GBP and CBZ 
[10]. 
 
Combination therapy is an effective strategy in 
neuropathy treatment, where a reduction of dose 
could decrease unpleasant side effects while 
producing effective analgesic outcomes. This 
study was carried out to investigate the 
effectiveness of GBP and CBZ combination 
therapy in the management of diabetic 
neuropathy pain in a rat model.  
 
EXPERIMENTAL  
 
Experimental animals 
 
Seventy adult female Sprague-Dawley rats 
weighing between 225 and 250 g were used. All 
animals were housed in groups of 2 - 3 at a 
temperature 22 ± 1 ºC and relative humidity of 60 
– 70 %, in a room with a 12:12 h light/dark cycle. 
The animals were allowed free access to water 
and normal diet. All experimental protocols 
involving animals and their care were approved 
(ref. no. IACUC-IIUM/2015-6-34) by the 
institutional animal care and used committee of 
International Islamic University Malaysia, and the 
experimental protocols followed the “Guide for 
the care and use of laboratory animals” [11]. 
 
Induction of diabetes 
 
STZ (Merck) was dissolved in 0.1 M Citrate 
Buffer at pH 4.5 immediately before 
intraperitoneally (i.p) injection. To induce 
diabetes, rats received a single i.p. injection of 
STZ (60 mg/kg body weight) following an 
overnight fast. Hyperglycaemia was confirmed 
three days later by the measurement of tail-vein 
blood-glucose concentration in fasting rats. Only 
animals with a blood glucose of 15 mmol/L or 
above were considered diabetic and used for the 
experiments. 
 
Drug administration 
 
Gabapentin (Neurontin, Pfizer, USA) was 
suspended in 0.9 % saline and administered 
three times daily. Liquid Carbamazepine 
(Novartis, Switzerland) was administered once 
daily; all drugs were administered to rats by oral 
gavage. 
 
Experimental design 
 
The rats were divided into seven groups of ten 
animals. 
 
Group I: Diabetic (STZ) + GBP 180 mg/kg: 
Animals received oral gavage of GBP (180 
mg/kg) daily for 1 week after four weeks of 
diabetes induction. 
 
Group II: Diabetic (STZ) +GBP 90 mg/kg: 
Animals received oral gavage of GBP (90 mg/kg) 
daily for 1 week after four weeks of diabetes 
induction. 
 
Group III: Diabetic (STZ) +CBZ 40 mg/kg: 
Animals received oral gavage of CBZ (40 mg/kg) 
daily for 1 week after four weeks of diabetes 
induction. 
 
Group IV: Diabetic (STZ) +CBZ 20 mg/kg: 
Animals received oral gavage of CBZ (20 mg/kg) 
daily for 1 week after four weeks of diabetes 
induction. 
 
Group V: Diabetic (STZ) + (GBP 90 mg/kg+ CBZ 
20 mg/kg): Animals received oral gavage of GBP 
90 mg/kg+ CBZ 20 mg/kg daily for 1 week after 
four weeks of diabetes induction. 
 
Group VI: Diabetic (STZ) + (GBP 30 mg/kg+ CBZ 
40 mg/kg): Animals received oral gavage of GBP 
30 mg/kg+ CBZ 40 mg/kg daily for 1 week after 
four weeks of diabetes induction. 
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Table 1: Dose calculation 
 
Group Animal dose 
(mg/kg) 
Human equivalent dose* 
(mg/kg) 
Human equivalent dose* (Total 
daily dose for adult 60kg) 
I 180 GBP 30 GBP 1800 GBP 
II 90 GBP 15 GBP 900 GBP 
III 40 CBZ 7 CBZ 400 CBZ 
IV 20 CBZ 3.5 CBZ 200 CBZ 
V 90 GBP + 20 CBZ 15 GBP + 3.5 CBZ 900 GBP + 200 CBZ 
VI 30 GBP + 40 CBZ 5 GBP + 7 CBZ 300 GBP + 400 CBZ 
VII Control 0.9 % saline - - 
* Approximate; Human Km= 37, Animal Km = 6; Oral LD50 of CBZ in rats, 3850-4025 mg/kg, NOVARTIS; Oral 
LD50 of GBP in rat > 5000 mg/kg, Pfizer 
 
Group VII: Diabetic (STZ) Control: Animals 
received oral gavage of 0.9 % saline daily for 1 
week after four weeks of diabetes induction. 
 
Dose calculation 
 
All doses were calculated by using the formula 
for dose translation based on body surface area: 
Animal equivalent dose (mg/kg) = Human dose 
(mg/kg)/(Animal Km/Human Km) [12] (Table 1). 
 
Hot plate test 
 
Hyperalgesic reaction on the hot plate test is 
produced from a combination of the central and 
peripheral mechanism [13]. Noxious thermal 
stimulus was administered to rats by placing 
them on a hot plate analgesia meter (model 144-
E52 Columbus, USA) maintained at 53 °C for 15 
min before the experiment. Drugs were orally 
administered via oral gavage method for 1 week 
after four weeks of diabetes induction. The 
reaction time (hot-plate latency) was recorded. 
The reaction time was taken as the time between 
placing the rats on the hot plate and the time 
when they licked their paws. A cut-off time of 60 
sec was used to prevent any thermal injury to the 
rats. 
 
Statistical analysis  
 
Results were expressed as mean ± SEM, and 
were analyzed by one-way analysis of variance 
(ANOVA). Significant differences between 
groups were determined by Dunnett test for 
multiple post-hoc comparisons using IBM SPSS 
Statistics 20 software. Statistical significance was 
accepted at p < 0.05. 
 
RESULTS 
 
Analgesia 
 
The analgesic effect of CBZ, GBP and their 
combinations on acute thermal nociception were 
tested using hot-plate test. Hot plate latencies 
significantly increased with oral administration of 
GBP at a dose of 180 mg/kg when compared 
with control group (p < 0.05), while at a dose of 
90 mg/kg, the increase was not statistically 
significant. Oral administration of CBZ at doses 
of 20 and 40 mg/kg did not produce any 
significant effect on the hot plate latencies. 
However, combination of GBP at 90 mg/kg and 
CBZ at 20 mg/kg produced a significant increase 
in the hot plate latencies relative to the control 
group, and other groups (p < 0.05) except group 
I (GBP 180mg/kg). The combination of GBP and 
CBZ at 30 mg/kg and 40 mg/kg, respectively 
caused slightly increases in hot plate latencies 
though this was not significant when compared to 
the other groups (Figure 1). 
 
DISCUSSION 
 
STZ is highly toxic for β-cells and is widely used 
to produce rodent models of type 1 diabetes. The 
progress of STZ induced diabetic neuropathy is 
primarily dependent on high glucose level, and 
on the duration of the high glucose level. In the 
early stage of diabetes in STZ rats, allodynia and 
hyperalgesia appeared to be induced during the 
first month of the onset of hyperglycemia in STZ 
rats [14]. Relative progression towards 
degenerative neuropathy is delayed in STZ-
diabetic rats and at least transiently, they show 
indices of allodynia and hyperalgesia that make 
them a viable model for studying aspects of 
painful diabetic neuropathy [15]. 
 
The mechanism of neuropathic pain is 
manifested at two levels: the peripheral and 
central levels. On the peripheral level, there is an 
up-regulation of sodium channels in areas of 
axonal damage leading to decreased threshold 
and ectopic discharges. On the spinal level, there 
is an increased entry of calcium into the cell and 
potentiation of calcium-mediated effects [16]. 
 
CBZ appears to limit the repetitive firing of action 
potentials evoked by a sustained depolarization 
by reducing the rate of recovery of voltage-
activated Na+ channels. At therapeutic doses, 
CBZ is selective in that there are no effects on  
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Figure 1: Reactions of different groups in the hot-plate test, group I (GBP 180 mg/kg), group II (GBP 90 mg/kg), 
group III (CBZ 40 mg/kg), group IV (CBZ 20 mg/kg), group V (GBP 90 mg/kg+ CBZ 20 mg/kg), group VI (GBP 30 
mg/kg+ CBZ 40 mg/kg) and group VII (control, 0.9 % saline). Mean ± S.E.M. data was analyzed by one-way 
ANOVA. Multiple comparisons was done by Dunnett's post hoc test (IBM SPSS Statistics 20 software). Statistical 
significance was accepted for a p-value of < 0.05 at 95 % confidence interval (CI). * p < 0.05, ** p < 0.001; GBP = 
gabapentin; CBZ = carbamazepine 
 
spontaneous activity or responses to GABA or 
glutamate [7].  
 
GBP acts by binding to the alpha-2-delta subunit 
of the calcium channel reducing neurotransmitter 
release. It is an antiepileptic drug with a structure 
similar to GABA, which is a neurotransmitter that 
plays a role in the pain mechanism [8].  GBP acts 
centrally to reduce hyperalgesia and allodynia, 
but it does not have significant actions as an anti-
nociceptive agent [17]. In contrast, CBZ 
preferentially suppressed thermal nociception, 
due partly to the local anaesthetic action of 
sodium channel blocking agents, and differential 
sensitivities of the fibers activated by thermal 
nociception to local anaesthetic [18].  
 
Previous clinical study has demonstrated 
absence of pharmacokinetic interactions 
between these combined therapies, along with 
the possibility of minimizing adverse effects, 
while significantly improving pain control in 
Trigeminal Neuralgia in Multiple Sclerosis [19]. 
No pharmacokinetic interaction exists between 
CBZ and GBP and dose adjustments are not 
necessary when GBP and CBZ are concurrently 
used [20]. 
 
CONCLUSION 
 
The combination of GBP and CBZ in the hot-
plate test at doses equivalent to human 
therapeutic doses of the two drugs was more 
efficacious than GBP and CBZ the drugs were 
given separately. Combining two medications 
with different mechanisms of action is a common 
strategy in the treatment of many medical 
disorders. The aim is to achieve a synergistic 
effect in the drug treatment, especially if there is 
no interaction between the drugs. The findings in 
this study provide additional data concerning 
combined treatment of pain in diabetic 
neuropathy with GBP and CBZ. 
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